Clik here to view.
Metabolic Solutions Announces New Findings in Diabetes Treatment
Sarah Schmid Kalamazoo, MI-based Metabolic Solutions Development Company, a company formed to develop drugs and discover new molecular targets in the treatment of insulin resistance, spent the weekend...
View ArticleClik here to view.
ViaCyte CEO Says $10M Grant Will Move Stem Cell Therapy to Trial
View the Slideshow Bruce V. Bigelow A $10.1 million grant the California Institute for Regenerative Medicine (CIRM) awarded to ViaCyte last week will be used to move the San …
View ArticleClik here to view.
Abide Therapeutics and Merck Unveil Diabetes Drug Collaboration
Bruce V. Bigelow Abide Therapeutics, a two-year-old San Diego biopharmaceutical firm pioneering new ways to identify and validate drug targets among the serine hydrolase “superfamily” of enzymes, says...
View ArticleClik here to view.
Array Biopharma Cuts Staff by 20%, Loses Development Deal with Amgen
Michael Davidson Array Biopharma, a Boulder, CO-based drug development company, announced today it has laid off 20 percent of its staff and that Amgen has ended a drug development …
View ArticleClik here to view.
PureTech Ventures, JDRF Team Up to Form Type 1 Diabetes Startup Creator
Ben Fidler Disease foundations often give money to startups working on treatments that might help the people they advocate for. But it’s not too often you’ll see a nonprofit foundation …
View ArticleClik here to view.
Relypsa Aims to Delay Need for Costly Dialysis in Kidney Patients
Bernadette Tansey These days, drug developers are trying to do more than persuade the FDA that their products work well in patients. To increase the market appeal of their products, …
View ArticleClik here to view.
Seattle’s KinDex Gets $5M to Fight Diabetes, Burn Fat With Hops
Ben Fidler Hops give a distinctive bitter taste to beer, which has been known to cause many a drinker to pack on an extra pound or two. But a Seattle-based …
View ArticleOverstreet, Winner in Startup Tax Battle, Gets $2M for AdverseEvents
Wade Roush When patients have bad reactions to prescription drugs, doctors can voluntarily submit reports about such “adverse events” to the Food and Drug Administration. The FDA gets at least …
View ArticleClik here to view.
So Far, Little Proof That Digital Health Is Healthy. Does It Matter?
Alex Lash Digital health is popular among investors, there’s no doubt. But is it good for us? Products such as fitness wristbands and online wellness coaching are generating buzz, and …
View ArticleClik here to view.
Servier Inks $1B Deal for Intarcia’s Implantable Diabetes Device
Ben Fidler It’s been a big year for Intarcia Therapeutics. The Boston- and Hayward, CA-based firm raised a massive round of private financing for its experimental drug/device combo treatment for (Read...
View ArticleRethinking Venture Philanthropy After the Kalydeco Windfall
Peter Kolchinsky The Cystic Fibrosis (CF) Foundation’s big win in venture philanthropy can fuel constructive competition among companies developing innovative CF drugs, benefiting both patients and...
View Article
